PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
Jun Ma(Shanghai Institute of Technology), Yu‐Pei Chen(Sun Yat-sen University), Fang‐Yun Xie(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Mei Shi(Xijing Hospital), Nian‐Yong Chen(Sichuan University), Shubin Hong(Sun Yat-sen University), Ying Sun(Key Laboratory of Guangdong Province), Feng Jin(China Medical University), Ling‐Long Tang(Sun Yat-sen University), Kunyu Yang(Macau University of Science and Technology), Yan‐Ping Mao(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Na Liu(Sun Yat-sen University), Ning Zhang(First People's Hospital of Foshan), Xiaodong Zhu(Guangxi Medical University), Zhen‐Yu He(Wuhan University of Technology), Liangfang Shen(Central South University), Guorong Zou(Panyu District Central Hospital), Hongyun Zhao(Sun Yat-sen University)
Cited by 19
Related Papers
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy
|PLoS ONE|2012|703
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3
|Cancer Research|2019|423
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393